Does the media refer more to DWTX or ARCT?

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Arcturus Therapeutics' score of 0.64 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KPTI or DWTX?

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Karyopharm Therapeutics' score of 0.63 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, IMUX or DWTX?

Immunic is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is IMUX or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Dogwood Therapeutics N/A -108.57% -30.28%

Does the media prefer IMUX or DWTX?

In the previous week, Immunic had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Immunic and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Immunic's score of 0.73 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DWTX or KRRO?

In the previous week, Korro Bio had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Korro Bio and 2 mentions for Dogwood Therapeutics. Korro Bio's average media sentiment score of 1.01 beat Dogwood Therapeutics' score of 0.93 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NKTX or DWTX?

Nkarta is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is NKTX or DWTX more profitable?

Nkarta's return on equity of -30.90% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Dogwood Therapeutics N/A -108.57% -30.28%

Does the media refer more to NKTX or DWTX?

In the previous week, Nkarta and Nkarta both had 2 articles in the media. Nkarta's average media sentiment score of 0.94 beat Dogwood Therapeutics' score of 0.93 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dogwood Therapeutics (DWTX) Competitors

$1.50 -0.11 (-6.83%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$1.61 +0.11 (+7.53%)

As of 09:20 AM Eastern

Compare

DWTX vs. ARCT, KPTI, IMUX, KRRO, and NKTX

Should you buy Dogwood Therapeutics stock or one of its competitors? MarketBeat compares Dogwood Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dogwood Therapeutics include Arcturus Therapeutics (ARCT), Karyopharm Therapeutics (KPTI), Immunic (IMUX), Korro Bio (KRRO), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

How does Dogwood Therapeutics compare to Arcturus Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Arcturus Therapeutics' score of 0.64 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 700.00%. Arcturus Therapeutics has a consensus price target of $24.25, suggesting a potential upside of 251.96%. Given Dogwood Therapeutics' higher possible upside, equities analysts clearly believe Dogwood Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Dogwood Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market.

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dogwood Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

Dogwood Therapeutics has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Arcturus Therapeutics	$82.03M	2.39	-$65.78M	-$2.81	N/A

Summary

Arcturus Therapeutics beats Dogwood Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Karyopharm Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Karyopharm Therapeutics' score of 0.63 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Karyopharm Therapeutics presently has a consensus price target of $17.17, indicating a potential upside of 79.76%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 700.00%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dogwood Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$151.12M	1.43	-$196.04M	-$15.09	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Dogwood Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Karyopharm Therapeutics and Dogwood Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Immunic?

Immunic (NASDAQ:IMUX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Immunic currently has a consensus target price of $47.57, suggesting a potential upside of 221.21%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 700.00%. Given Dogwood Therapeutics' higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Immunic had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Immunic and 2 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.93 beat Immunic's score of 0.73 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.8% of Immunic shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Immunic has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

Immunic is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Dogwood Therapeutics' return on equity of -108.57% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Summary

Immunic and Dogwood Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Korro Bio?

Dogwood Therapeutics (NASDAQ:DWTX) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Dogwood Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Dogwood Therapeutics' return on equity of -108.57% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Dogwood Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market.

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dogwood Therapeutics has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Korro Bio	$3.84M	51.24	-$117.26M	-$11.67	N/A

In the previous week, Korro Bio had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 4 mentions for Korro Bio and 2 mentions for Dogwood Therapeutics. Korro Bio's average media sentiment score of 1.01 beat Dogwood Therapeutics' score of 0.93 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 700.00%. Korro Bio has a consensus target price of $16.71, indicating a potential upside of 22.45%. Given Dogwood Therapeutics' higher probable upside, research analysts clearly believe Dogwood Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

Korro Bio beats Dogwood Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Nkarta has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

In the previous week, Nkarta and Nkarta both had 2 articles in the media. Nkarta's average media sentiment score of 0.94 beat Dogwood Therapeutics' score of 0.93 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Nkarta currently has a consensus target price of $10.75, suggesting a potential upside of 277.19%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 700.00%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nkarta's return on equity of -30.90% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Nkarta beats Dogwood Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.14M	$3.66B	$6.79B	$12.60B
Dividend Yield	N/A	2.21%	2.66%	6.14%
P/E Ratio	-0.14	21.28	27.41	25.28
Price / Sales	N/A	339.41	533.66	99.00
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	0.64	8.71	11.02	6.62
Net Income	-$34.26M	$23.87M	$3.57B	$336.83M
7 Day Performance	1.35%	4.34%	2.90%	3.25%
1 Month Performance	-10.18%	6.62%	3.71%	0.92%
1 Year Performance	-68.94%	61.64%	34.39%	27.62%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	3.2562 of 5 stars	$1.50 -6.8%	$12.00 +700.0%	-69.7%	$54.14M	N/A	N/A	5
ARCT Arcturus Therapeutics	2.3875 of 5 stars	$7.08 -2.1%	$25.44 +259.4%	-47.0%	$205.50M	$82.03M	N/A	180	News Coverage
KPTI Karyopharm Therapeutics	1.8904 of 5 stars	$9.65 +7.2%	$17.17 +77.9%	+119.0%	$203.97M	$146.07M	N/A	380	News Coverage High Trading Volume
IMUX Immunic	3.6273 of 5 stars	$15.07 +2.2%	$47.57 +215.7%	+114.5%	$200.92M	N/A	N/A	70	News Coverage
KRRO Korro Bio	2.8899 of 5 stars	$13.71 -1.4%	$16.71 +21.9%	+6.9%	$200.47M	$6.39M	N/A	70	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. ARCT, KPTI, IMUX, KRRO, and NKTX

How does Dogwood Therapeutics compare to Arcturus Therapeutics?

Summary

How does Dogwood Therapeutics compare to Karyopharm Therapeutics?

Summary

How does Dogwood Therapeutics compare to Immunic?

Summary

How does Dogwood Therapeutics compare to Korro Bio?

Summary

How does Dogwood Therapeutics compare to Nkarta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. ARCT, KPTI, IMUX, KRRO, and NKTX

How does Dogwood Therapeutics compare to Arcturus Therapeutics?

Does the media refer more to DWTX or ARCT?

Do analysts prefer DWTX or ARCT?

Which has more risk and volatility, DWTX or ARCT?

Do institutionals and insiders hold more shares of DWTX or ARCT?

Is DWTX or ARCT more profitable?

Which has stronger earnings and valuation, DWTX or ARCT?

Summary

How does Dogwood Therapeutics compare to Karyopharm Therapeutics?

Which has more risk & volatility, KPTI or DWTX?

Does the media refer more to KPTI or DWTX?

Do analysts rate KPTI or DWTX?

Which has higher valuation & earnings, KPTI or DWTX?

Is KPTI or DWTX more profitable?

Do institutionals & insiders believe in KPTI or DWTX?

Summary

How does Dogwood Therapeutics compare to Immunic?

Do analysts recommend IMUX or DWTX?

Does the media prefer IMUX or DWTX?

Do institutionals and insiders hold more shares of IMUX or DWTX?

Which has more volatility and risk, IMUX or DWTX?

Which has stronger earnings & valuation, IMUX or DWTX?

Is IMUX or DWTX more profitable?

Summary

How does Dogwood Therapeutics compare to Korro Bio?

Is DWTX or KRRO more profitable?

Which has more risk & volatility, DWTX or KRRO?

Do insiders & institutionals believe in DWTX or KRRO?

Which has preferable earnings & valuation, DWTX or KRRO?

Does the media favor DWTX or KRRO?

Do analysts rate DWTX or KRRO?

Summary

How does Dogwood Therapeutics compare to Nkarta?

Which has more risk & volatility, NKTX or DWTX?

Does the media refer more to NKTX or DWTX?

Which has higher earnings and valuation, NKTX or DWTX?

Do analysts prefer NKTX or DWTX?

Is NKTX or DWTX more profitable?

Do institutionals & insiders hold more shares of NKTX or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools